JP2024534454A5 - - Google Patents
Info
- Publication number
- JP2024534454A5 JP2024534454A5 JP2024516972A JP2024516972A JP2024534454A5 JP 2024534454 A5 JP2024534454 A5 JP 2024534454A5 JP 2024516972 A JP2024516972 A JP 2024516972A JP 2024516972 A JP2024516972 A JP 2024516972A JP 2024534454 A5 JP2024534454 A5 JP 2024534454A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- sequence
- cdrh2
- cdrh1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245499P | 2021-09-17 | 2021-09-17 | |
| US63/245,499 | 2021-09-17 | ||
| PCT/US2022/076522 WO2023044402A1 (en) | 2021-09-17 | 2022-09-16 | Anti-cd3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534454A JP2024534454A (ja) | 2024-09-20 |
| JP2024534454A5 true JP2024534454A5 (enExample) | 2025-09-19 |
Family
ID=85603635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516972A Pending JP2024534454A (ja) | 2021-09-17 | 2022-09-16 | 抗ｃｄ３抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240317858A1 (enExample) |
| EP (1) | EP4377360A4 (enExample) |
| JP (1) | JP2024534454A (enExample) |
| KR (1) | KR20240102947A (enExample) |
| CN (1) | CN118339182A (enExample) |
| AU (1) | AU2022347432A1 (enExample) |
| CA (1) | CA3231006A1 (enExample) |
| IL (1) | IL311039A (enExample) |
| MX (1) | MX2024003355A (enExample) |
| TW (1) | TW202325734A (enExample) |
| WO (1) | WO2023044402A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021014973A (es) * | 2019-06-07 | 2022-04-18 | Adimab Llc | Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. |
| MX2023010541A (es) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Proteinas de union al antigeno del peptido del mhc mage-a4. |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| CA3264474A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT |
| US20240228620A1 (en) | 2022-10-06 | 2024-07-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| WO2024254192A2 (en) * | 2023-06-05 | 2024-12-12 | Suntec Medical, Inc. | Method for treating neurodegenerative diseases |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| EP4590714A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| EP4590715A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025240781A2 (en) * | 2024-05-15 | 2025-11-20 | Werewolf Therapeutics, Inc. | Modified antibodies and immunoglobulin formats |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2026006458A1 (en) * | 2024-06-25 | 2026-01-02 | Adimab, Llc | Anti-cd3 antibodies and compositions and methods related thereto |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118894936A (zh) * | 2017-05-08 | 2024-11-05 | 阿迪马布有限责任公司 | 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法 |
| JP7383704B2 (ja) * | 2018-06-07 | 2023-11-20 | カリナン オンコロジー インコーポレイテッド | 多重特異性結合タンパク質およびその使用方法 |
| MX2021014973A (es) * | 2019-06-07 | 2022-04-18 | Adimab Llc | Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. |
| CN119874917A (zh) * | 2019-06-07 | 2025-04-25 | 阿迪马布有限责任公司 | 工程化的pH依赖性抗CD3抗体及其产生和使用方法 |
| KR20220045030A (ko) * | 2019-08-17 | 2022-04-12 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도 |
| US20220306760A1 (en) * | 2019-08-23 | 2022-09-29 | Igm Biosciences, Inc. | Igm glycovariants |
-
2022
- 2022-09-16 EP EP22870965.5A patent/EP4377360A4/en active Pending
- 2022-09-16 JP JP2024516972A patent/JP2024534454A/ja active Pending
- 2022-09-16 AU AU2022347432A patent/AU2022347432A1/en active Pending
- 2022-09-16 KR KR1020247012717A patent/KR20240102947A/ko active Pending
- 2022-09-16 CN CN202280068976.5A patent/CN118339182A/zh active Pending
- 2022-09-16 CA CA3231006A patent/CA3231006A1/en active Pending
- 2022-09-16 US US18/692,097 patent/US20240317858A1/en active Pending
- 2022-09-16 WO PCT/US2022/076522 patent/WO2023044402A1/en not_active Ceased
- 2022-09-16 TW TW111135172A patent/TW202325734A/zh unknown
- 2022-09-16 MX MX2024003355A patent/MX2024003355A/es unknown
- 2022-09-16 IL IL311039A patent/IL311039A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12359001B2 (en) | Method for producing polypeptide hetero-oligomer | |
| JP2024534454A5 (enExample) | ||
| US20240317858A1 (en) | Anti-cd3 antibodies | |
| IL270366B2 (en) | Anti-CD3-binding sites and antibodies containing them, and methods of making and using them | |
| JP2020518650A5 (enExample) | ||
| US20160229915A1 (en) | Method for producing polypeptide heteromultimer | |
| US20230348577A1 (en) | Modified fc regions | |
| US20230002487A1 (en) | High affinity anti-cd3 antibodies, and methods for their generation and use | |
| US20230365694A1 (en) | IMMUNOSILENCING Fc VARIANTS | |
| US20250019439A1 (en) | Anti-idiotype antibodies | |
| EP4255933A1 (en) | Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use | |
| US20240209062A1 (en) | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use | |
| CN119219775A (zh) | 与FcRn结合减弱的Fc变体 | |
| RU2024109201A (ru) | Антитела к cd3 | |
| US20250163166A1 (en) | Antibody comprising igg fc region variant, and use thereof | |
| RU2024136825A (ru) | Высокоаффинные антитела к cd3 и способы их получения и применения | |
| RU2021138136A (ru) | Высокоаффинные антитела к cd3 и способы их получения и применения | |
| KR20250151402A (ko) | 반려 동물에서 사용하기 위한 이중특이적 결합제 | |
| RU2021138150A (ru) | Сконструированные ph-зависимые антитела к cd3, а также способы их получения и применения | |
| RU2024136954A (ru) | Сконструированные ph-зависимые антитела к cd3, а также способы их получения и применения | |
| HK40115880A (zh) | 具有与fcgammar和c1q的消除的结合的fc变体 | |
| HK40115364A (zh) | 具有与fcgammar和c1q的消除的结合的fc变体 |